An animal model is a non-human animal species used in biomedical research because it can mimic aspects of a biological process or disease that occur in humans.
Darobactin is a promising candidate for the development of new, resistance-breaking antibiotics, as it has an exceptional mechanism of action and a broad spectrum of activity. In a recent study, DZIF
The Faculty of Medicine at the University of Basel has awarded an honorary doctorate to DZIF Professor Dr Stephan Urban from the Medical Faculty at the Heidelberg University. The award acknowledges
Please use the picture only in connection with the press release.
Antibiotic-resistant bacteria pose a major challenge to healthcare systems worldwide. Due to numerous resistance mechanisms, infections with the pathogenPseudomonas aeruginosa are particularly feared
Affecting hundreds of millions of people, chronic hepatitis B is a widespread global health problem for which there is as yet no cure. In a preclinical study involving the German Center for Infection
Bitte verwenden Sie dieses Bild nur in Zusammenhang mit der Pressemitteilung.
Researchers of the German Center for Infection Research (DZIF) at the Paul-Ehrlich-Institut (PEI) and Philipps-Universität Marburg used the "recombinant measles virus" vaccine platform to test vaccine
Please use image only in conjunction with press release.
Antibiotics affect the composition and dynamics of the gut microbiome. Treatment with antibiotics not only leads to a loss of biodiversity of microorganisms, but also often favours the selection of
Scanning electron micrograph: C. difficile cells were provided by Nicole Metzendorf from the Department of Microbial Physiology and Molecular Biology, Institute of Microbiology, and imaged by Rabea Schlüter, Imaging Center of the Department of Biology, University of Greifswald, Germany.
Please use this image only in connection with this press release.
Infections with the bacterium Clostridioides difficile (C. difficile for short) frequently recur due to permanent stages remaining in the intestine. A drug that also effectively combats the permanent
EBViously, a spin-off from Helmholtz Munich (HMGU), is led by world-leading experts in Epstein-Barr virus biology, genetics, and immunity and was founded to develop a safe and highly effective